Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-center, observational, retrospective study assessing the role of Absolute Eosinophil Counts as a predictive biomarker of immune-related adverse events in patients with metastatic Renal Cell Carcinoma treated with Immune Checkpoint Inhibitors

Next Previous
Trial Profile

A single-center, observational, retrospective study assessing the role of Absolute Eosinophil Counts as a predictive biomarker of immune-related adverse events in patients with metastatic Renal Cell Carcinoma treated with Immune Checkpoint Inhibitors

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Pharmacodynamics

Most Recent Events

  • 19 Mar 2021 New trial record
  • 13 Feb 2021 Results presented at the 2021 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top